Atlas Trials

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Clinical trial NCT02937675 · TERMINATED

Trial details

NCT number
NCT02937675
Sponsor
Effector Therapeutics
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2017-02-08
Primary completion
2018-11-12
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.